Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2008; 52:1968-1977, doi:10.1016/j.jacc.2008.07.068
© 2008 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow View Related Cardiosource Journal Scan
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Erlinge, D.
Right arrow Articles by Wallentin, L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Erlinge, D.
Right arrow Articles by Wallentin, L.
Related Collections
Right arrowRelated Articles

CLINICAL RESEARCH: ANTIPLATELET THERAPY

Patients With Poor Responsiveness to Thienopyridine Treatment or With Diabetes Have Lower Levels of Circulating Active Metabolite, but Their Platelets Respond Normally to Active Metabolite Added Ex Vivo

David Erlinge, MD, PhD*,*, Christoph Varenhorst, MD{dagger}, Oscar Ö. Braun, MD, PhD*, Stefan James, MD, PhD{dagger}, Kenneth J. Winters, MD§, Joseph A. Jakubowski, PhD§, John T. Brandt, MD§, Atsuhiro Sugidachi, PhD||, Agneta Siegbahn, MD, PhD{ddagger} and Lars Wallentin, MD, PhD{dagger}

* Department of Cardiology, Lund University, Lund, Sweden
{dagger} Uppsala Clinical Research Centre and Department of Medical Sciences, Uppsala University, Uppsala, Sweden
{ddagger} Coagulation Laboratory, Department of Medical Sciences, Uppsala University, Uppsala, Sweden
§ Lilly Research Laboratories, Indianapolis, Indiana
|| Daiichi Sankyo Co., Ltd., Tokyo, Japan

Manuscript received April 28, 2008; revised manuscript received June 16, 2008, accepted July 10, 2008.

* Reprint requests and correspondence: Dr. David Erlinge, Department of Cardiology, Lund University Hospital, SE-221 85, Lund, Sweden (Email: david.erlinge{at}med.lu.se).

Objectives: We evaluated the prevalence and mechanism of poor responsiveness to clopidogrel and prasugrel in coronary artery disease patients with and without diabetes.

Background: Low platelet inhibition by clopidogrel is associated with ischemic clinical events. A higher 600-mg loading dose (LD) has been advocated to increase responsiveness to clopidogrel.

Methods: In this study, 110 aspirin-treated patients were randomized to double-blind treatment with clopidogrel 600 mg LD/75 mg maintenance dose (MD) for 28 days or prasugrel 60 mg LD/10 mg MD for 28 days. Pharmacodynamic (PD) response was evaluated by light transmission aggregometry and vasodilator-stimulated phosphoprotein phosphorylation. The PD poor responsiveness was defined with 4 definitions previously associated with worse clinical outcomes. Active metabolites (AM) of clopidogrel and prasugrel were measured. Clopidogrel AM was added ex vivo.

Results: The proportion of patients with poor responsiveness was greater in the clopidogrel group for all definitions at all time points from 1 h to 29 days. Poor responders had significantly lower plasma AM levels compared with responders. Patients with diabetes were over-represented in the poor-responder groups and had significantly lower levels of AM. Platelets of both poor responders and diabetic patients responded fully to AM added ex vivo.

Conclusions: Prasugrel treatment results in significantly fewer PD poor responders compared with clopidogrel after a 600-mg clopidogrel LD and during MD. The mechanism of incomplete platelet inhibition in clopidogrel poor-responder groups and in diabetic patients is lower plasma levels of its AM and not differences in platelet P2Y12 receptor function.

Key Words: prasugrel • trials • thienopyridine • clopidogrel • platelets • clopidogrel resistance • coronary artery disease

Abbreviations and Acronyms
  ADP = adenosine 5'-diphosphate
  AM = active metabolite
  AUC = area under the curve
  LD = loading dose
  LTA = light transmission aggregometry
  MD = maintenance dose
  MPA = maximal platelet aggregation
  PCI = percutaneous coronary intervention
  PD = pharmacodynamic
  PRI = platelet reactivity index
  RPA = residual platelet aggregation
  VASP = vasodilator-stimulated phosphoprotein


Related Articles

The Pursuit of Clinically Relevant Measures of Platelet Function After Antiplatelet Drug Therapy
John A. Cairns and John Eikelboom
J. Am. Coll. Cardiol. 2008 52: 1978-1980. [Full Text] [PDF]

Inside This Issue of JACC
J. Am. Coll. Cardiol. 2008 52: A32. [Full Text] [PDF]



This article has been cited by other articles:


Home page
Eur Heart JHome page
U. Stenestrand, S. K. James, J. Lindback, O. Frobert, J. Carlsson, F. Schersten, T. Nilsson, B. Lagerqvist, and for the SCAAR/SWEDEHEART study group
Safety and efficacy of drug-eluting vs. bare metal stents in patients with diabetes mellitus: long-term of follow-up in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
Eur. Heart J., November 10, 2009; (2009) ehp424v1.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. P. Giugliano and E. Braunwald
The Year in Non-ST-Segment Elevation Acute Coronary Syndrome.
J. Am. Coll. Cardiol., October 13, 2009; 54(16): 1544 - 1555.
[Full Text] [PDF]


Home page
Eur Heart JHome page
L. Wallentin
P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use
Eur. Heart J., August 2, 2009; 30(16): 1964 - 1977.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
N. B Norgard, K. D Mathews, and G. C Wall
Drug-Drug Interaction Between Clopidogrel and the Proton Pump Inhibitors
Ann. Pharmacother., July 1, 2009; 43(7): 1266 - 1274.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. A. Cairns and J. Eikelboom
The Pursuit of Clinically Relevant Measures of Platelet Function After Antiplatelet Drug Therapy
J. Am. Coll. Cardiol., December 9, 2008; 52(24): 1978 - 1980.
[Full Text] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement